Introduction
Cancer metastasis is a sequential and selective process that consists of a series of interlinked, but independent steps, including angiogenesis, motility, invasion, adhesion, extravasation and proliferation. 1 Angiogenesis has been studied extensively, but lymphangiogenesis is a relatively new topic in vascular biology. Lymphangiogenesis and lymph-node metastasis are important for the spread of cancer. Lymph-node metastasis, a frequent occurrence in the early stages of many types of cancer, is considered a useful prognostic indicator. Therefore, the control of lymph-node metastasis is an important consideration in cancer treatment.
Angiogenesis is induced by various factors, including the vascular endothelial growth factor (VEGF) family of polypeptide growth factors. This family comprises VEGF-A, -B, -C, -D and -E, which are specific members of this family known to be required for cancer progression and metastasis. 2, 3 Among the VEGF family, VEGF-C has recently been found to induce not only angiogenesis, but also lymphangiogenesis, via both VEGF receptor (VEGFR)-2 and VEGFR-3. [4] [5] [6] Expression of VEGFR-3 is highly restricted to lymphatic endothelial cells and stimulated by only VEGF-C and -D. [7] [8] [9] VEGF-C overexpression in breast cancer potently increases intratumoral lymphangiogenesis, resulting in enhanced metastasis to regional lymph nodes. 10 Several reports have described a significant correlation between VEGF-C expression, tumor lymphangiogenesis and regional lymph-node metastasis in some tumors. [11] [12] [13] [14] [15] [16] [17] [18] Therefore, inhibition of VEGF-C activity or disabling VEGF-C receptor function may be useful to inhibit tumor growth and metastasis.
The first approved protocol of gene therapy for humans was in September 1990. 19 Since then, the genetic basis of many human diseases has been deciphered. However, efforts to use gene therapy to treat these diseases have been hampered due to the extreme difficulty in delivering the proper molecule to the appropriate cells or tissues. Therefore, development of a safe and effective gene delivery system is of crucial importance for gene therapy. Many vectors, including viral and nonviral vectors, have been used for gene therapy. All of them have some serious drawbacks, such as triggering an immune response, 20 severe hepatic inflammation, 21 random chromosomal integration 22 or cytotoxicity to the host cell. 23 Nanoparticles have emerged as very promising nonviral vectors because of their advantages over both viral and nonviral vectors: (1) they are safe; (2) cost-effective and (3) may also successfully overcome many limitations of the other vector types, such as risk of recombination, strong immunogenicity and carcinogenity.
It was recently shown that RNA interference is a process of a sequence-specific and post-transcriptional gene silencing. The silencing mechanism is triggered by double-stranded RNA that causes specific degradation of the homologous target mRNA. [24] [25] [26] [27] This new approach has been successfully applied to inhibit virus replication 28 and tumorigenicity. 29 Recent reports have described DNA vector-based strategies for delivery of small interfering RNA (siRNA) into mammalian cells. [30] [31] [32] These traits of RNA interference suggest that it could serve as an appropriate candidate for use as a gene therapy agent when coupled with an appropriate delivery system.
In the present study, we evaluate the physicochemical properties of the calcium carbonate (CaCO 3 ) nanoparticle, including its use as a vehicle for in vitro transfection of cells in culture. We also evaluate the efficiency of CaCO 3 nanoparticle as a siRNA-delivering agent in vitro by a VEGF-C inhibition assay and in vivo using tumor growth and lymphangiogenesis of SGC-7901 cells in a nude mouse model.
Materials and methods
Sodium dodecyl sulfate (SDS) was obtained as a 99% pure product from Biomol International (Plymouth Meeting, PA). Pluronic, agarose, sodium citrate, calcium chloride and sodium carbonate were purchased from Sigma-Aldrich (St Louis, MO). RPMI-1640 was purchased from Gibco BRL (Life Technologies, Gaithersburg, MD). SGC-7901 cell lines were purchased from the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences. The cells were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS; Invitrogen), 50 U ml À1 of penicillin and 50 mg ml À1 of streptomycin.
Preparation of calcium carbonate nanoparticles Calcium chloride (50 ml) (0.05 M), 10 ml of 1% SDS and 10 ml of 1% F68 were mixed by continuous stirring (300 r.p.m.) for 24 h to form microemulsion A; 50 ml of sodium carbonate (0.025 M), 50 ml of sodium citrate (0.025 M), 10 ml of 1% SDS and 10 ml 1% F68 were mixed by continuous stirring (300 r.p.m.) for 24 h to form microemulsion B. After 24 h, microemulsion B was slowly added to microemulsion A at the rate of 10 ml h À1 with continuous stirring (350 r.p.m.) at 35 1C and then further stirred for 72 h after centrifugation at 15 000 r.p.m. for 15 min. The pelleted nanoparticles were washed four times with 75% ethanol, redispersed in 15 ml of double-distilled water by sonication (frequency 22 kHz; power 120 W) for 1 h. The dispersed nanoparticles were quickly frozen at À70 1C for 2 h in an ultracold freezer, before being freeze dried over a 48 h period. The calcium carbonate nanoparticle powder was kept for use.
Particle size analysis and measurement of z potential A 20 ml portion of CaCO 3 nanoparticles were placed onto a carbon-coated copper grid, quickly washed in water and immersed in the contrast stain solution (0.04% uranyl acetate in methanol) for 1 min. Grids were blotted, airdried and examined by transmission electron microscopy (Hitachi H-600, Japan) at a magnification of Â 20 000. The z potential of the CaCO 3 nanoparticles was measured using Zetasizer 4 (Malven Instruments, Herrenberg, Germany).
Preparation and detection of CaCO 3 nanoparticles-DNA complexes
The suspension of CaCO 3 nanoparticle and plasmid DNA were mixed at several different ratios (15:1, 10:1, 5:1). The mixture was maintained in suspension for 30 min at room temperature, and centrifuged at 10 000 r.p.m. for 10 min. The supernatant was subjected to gel electrophoresis to identify unbound DNA.
Protection assay of DNA on the CaCO 3 nanoparticles The pEGFP-N1 DNA (4 mg) was mixed with RPMI 1640 media containing 10% w/v FBS or 10% w/v newborn serum, respectively. The two mixtures were incubated separately at 37 1C for 12 h. The CaCO 3 nanoparticle-DNA complex, containing 4 mg DNA and 60 mg CaCO 3 nanoparticles, was incubated with FBS or newborn serum at 37 1C for 12 h and then was centrifuged at 10 000 r.p.m. for 10 min. The supernatant was discarded and the pellet resuspended with TE (pH10). The CaCO 3 nanoparticle complex was detected by agarose gel electrophoresis.
Transfection in vitro
The CaCO 3 nanoparticle-DNA complex was prepared with mixing 2 mg pEGFP-N1 DNA and 30 mg CaCO 3 nanoparticles. The SGC-7901 cells were seeded in 12-well plates at a cell density of 2 Â 10 5 cells per well. The cells were allowed to adhere overnight as a monolayer and achieve 70-80% confluence. Cells cultured in a medium containing 10% (w/v) bovine serum were transfected by addition of the complex of CaCO 3 nanoparticles and pEGFP-N1 DNA to each well for 24 h. Liposomemediated pEGFP-N1 DNA (10:2 mg) was also applied to different SGC-7901 cells as a positive control. After 24 h of incubation, the transient expression of green fluorescent protein (GFP) was detected by using a confocal laser scanning microscopy (Radiance 2100, Bio-Rad, Hercules, CA) by counting the ratio of GFP-expressing cells to nonexpressing cells in four random fields, with a total of 600 cells in each field.
MTT assay
To determine the cytotoxicity of each vector, including the CaCO 3 nanoparticles, the CaCO 3 nanoparticle-DNA complexes and lipofectin on the SGC-7901 cell line, a tetrazolium dye-based (MTT) assay was applied. SGC-7901 cells were seeded into a 96-well plate (1 Â 10 3 cells per well), incubated for 24 h and then transfected with either CaCO 3 nanoparticles (25 mg ml ), respectively. After 4 days of transfection, the supernatant of the cell culture was removed and replaced with the fresh RPMI 1640 medium. This was followed by the addition of 20 ml of MTT solution (20 mg ml
À1
) to each well and incubation for a further 4 h. The reaction was stopped by addition of dimethyl sulfoxide (Promega, Madison, WI) and the optical density was determined at 490 nm on a multiwell plate reader (Bio-Rad mode 3550, Bio-Rad, Mississauga, Canada). Background absorbance of medium in the absence of cells was subtracted. All samples were assayed in duplicate, and the mean for each experiment was calculated. Results were expressed as a percentage of the control, which was set at 100%.
Plasmid and construction
The siRNA (sense and antisense strands) and siRNA expression vector pGenesil-1 were purchased from Genesil Biotechnology Corporation (Wuhan, China). The sense strand sequence was 5-GATCCGAAGTTCCAC CACCAAACATTCAAGAGATGTTTGGTGGTGGAA CTTCTTTTTTGGAAA-3, and the control sequence was 5-GATCCGTTCTCCGAACGTGTCACGTTTCAAGA GAACGTGACACGTTCGGAGAATTTTTTGGAAA-3, which has no significant homology to any sequence in the human or mouse genomes. The siRNA-expressing plasmid targeting human VEGF-C and the control plasmid were constructed according to the manufacturer's instructions. Briefly, the cDNA oligonucleotides of VEGF-C siRNA and control siRNA were synthesized by integrated DNA Technologies (Coraliville, Iowa). Both pairs of oligonucleotides were annealed at 90 1C for 3 min, cooled to 37 1C and then incubated for 1 h. The annealed doublestranded DNA oligonucleotides were ligated between the BamHI and HindIII sites on the pGenesil-1 vector. The inserted sequences were verified by DNA sequencing. The expression plasmid contains cDNA for GFP and kanamycin resistance gene.
Transfection of CaCO 3 nanoparticle-siRNA for gastric cancer therapy in vitro and in vivo Transient transfection of SGC-7901 cell line and collection of conditioned media. SGC-7901 cells were cultured in 160-mm dish in RPMI 1640, supplemented with 10% FBS at 37 1C in 5% CO 2 . When the cells grew to 70% confluence, the CaCO 3 nanoparticle-siRNA (ratio of 75:5 mg) complex was added to the cells. Forty-eight hours after transfection, cells were analyzed by fluorescence microscopy to calculate transfection efficiency. For each well, the number of cells in four random microscopic fields was counted and transfection efficiency for each sample was estimated as the mean value of GFPexpressing cells per 100 cells in each field. Conditioned media was collected and subjected to a short centrifugation (10 min at 1000 r.p.m.) to eliminate cellular debris.
Enzyme-linked immunosorbent assay. To quantify the amount of secreted VEGF-C in conditioned media of transfected cells, human gastric cancer VEGF-C enzymelinked immunosorbent assay (ELISA) was performed using human VEGF-C Duo Set ELISA kit (R&D systems, Minneapolis, MN) following the manufacturer's protocol. The assay was repeated at least twice. Results of the ELISA assay were expressed as pg VEGF-C per ml per 10 4 cells and were normalized for transfection efficiency.
Messenger RNA analysis. All RNA was extracted from cell lines SGC-7901 and tumor tissue using the TRIzol reagent following the manufacturer's protocol (Invitrogen). One-step SYBR real-time PCR of VEGF-C mRNA was performed according to the manufacturer's instructions (Takara, Tokyo, Japan). Briefly, 2 mg of RNA per sample was reverse transcribed into cDNA using random primers. The reverse transcription reaction proceeded at 42 1C for In vivo tumor xenograft model. A total of 30 male BALB/c nude mice of 5 weeks old were obtained from Shanghai Laboratory Animal Center of the Chinese Academy of Science and were treated according to the local ethics guidelines for animal research. A total of 2.0 Â 10 7 SGC-7901 cells in 0.1 ml of serum-free RPMI 1640 were injected subcutaneously with a 24-gauge needle into the right flank of each nude mouse. When tumor volume reached 65.5 ± 7.0 mm 3 , mice were randomized for therapy in three experimental groups.
For DNA therapy, animals were anesthetized with metadoxine (1 mg kg À1 ) and ketamine (75 mg kg
À1
), and either 50 mg of pGenesil-1-siRNA-VEGF-C, pGenesil-1-siRNA targeting vascular endothelial growth factor-C X-w He et al siRNA-control in 20 ml of sterile physiologic solution (0.9% NaCl) or phosphate-buffered saline (PBS) as a control was directly injected into the tumor mass. Tumor volume was determined weekly by external measurements with a caliper and calculated as V ¼ W 2 Â L/2, where W ¼ short diameter and L ¼ long diameter. The observations were terminated after 18 days from the day of DNA injection. Animals were killed and the tumors were immediately frozen in dry ice or fixed in formalin.
Immunohistochemical staining for VEGFR-3 expression. Tumors from mice that were injected with CaCO 3 nanoparticle-siVEGF-C complex or CaCO 3 nanoparticlecontrol plasmid complex were put into optimal cutting temperature compound (Sakura, Tokyo, Japan), and 6-8 mm thick sections were cut. VEGFR-3 immunolabeling was used as a proxy for lymphangiogenesis, and an anti-pan-cytokeratin antibody was used to determine lymph-node metastasis. Briefly, tissue sections were processed for immunohistochemistry using goat antimouse VEGFR-3 or anti-pan-cytokeratin antibodies. Immunoreactivity was detected using the ABC Elite Kit and 3,3 0 -diaminobenzidine substrate kits as per the manufacturer's instructions. A reddish-brown precipitate in the cytoplasm indicated a positive reaction. Negative controls included all reagents except the primary antibody. The number of positive cells was counted at Â 400 magnification in the area of highest intensity siRNA targeting vascular endothelial growth factor-C X-w He et al deemed significant. All statistical analyses were carried out using SPSS software.
Results

CaCO 3 nanoparticle
Transmission electron observations ( Â 10 000 and Â 30 000 magnification) revealed that the CaCO 3 nanoparticles were uniform and averaged between 50 and 60 nm in diameter (Figures 1a and b) . The z potential analysis showed a positive surface charge of þ 28.6 mV ( Figure 2 ) for the CaCO 3 nanoparticle suggesting that the CaCO 3 nanoparticle could bind to the negatively charged surface of the DNA chain through electrostatic interaction.
DNA-binding efficiency and protection of DNA from degradation DNA-binding efficiency was studied by electrophoretic mobility of the DNA within an agarose gel. The ratio of the CaCO 3 nanoparticle to DNA ranged from 5:1 to 15:1. These results showed that the best ratio between CaCO 3 nanoparticle and DNA was 15:1 ( Figure 3 ) and CaCO 3 nanoparticle could protect DNA effectively from degradation ( Figure 4 ).
Transfection efficiency and cytotoxicity from CaCO 3 nanoparticle
High transfection efficiencies were achieved with both the nanoparticle (approximately 65%) and lipofection approaches (approximately 70%), indicating that the CaCO 3 nanoparticle is just as efficient as a vector for DNA transfer as is lipofection. However, lipofection results in cytotoxicity, while neither the CaCO 3 nanoparticle nor the CaCO 3 nanoparticle-DNA complex have any obvious cytotoxicity for SGC-7901 cells ( Figure 5 ).
VEGF-C-siRNA expression plasmid transfected via CaCO 3 nanoparticles inhibited VEGF-C-siRNA expression in vitro VEGF-C-siRNA-expressing plasmid pGenesil-1-VEGF-C siRNA and control plasmid pGenesil-1-CONT siRNA were constructed and transfected into SGC-7901 by CaCO 3 nanoparticle. VEGF-C mRNA levels were reduced by 81% in pGenesil-1-VEGF-C siRNA-transfected ; Figure 6b ). These data demonstrate that VEGF-C-siRNA expression plasmid transfected via CaCO 3 nanoparticles inhibited VEGF-C-siRNA expression in both mRNA and proteins in vitro. siRNA targeting vascular endothelial growth factor-C X-w He et al when the neoplastic mass was initially palpable. To determine the therapeutic effectiveness of VEGF-C siRNA, we started intratumoral treatment with either the CaCO 3 nanoparticle-siVEGF-C complex or the CaCO 3 nanoparticle-control siRNA complex. The treatment was repeated every 3 days for a total of five times. The CaCO 3 nanoparticle-siVEGF-C complex markedly suppressed tumor growth as compared to the CaCO 3 nanoparticle-control plasmid complex (Po0.05) or to PBS (Figures 7a and b) . To assess the relationship between the therapeutic effects of CaCO 3 nanoparticlesiVEGF-C complex and the presence of the VEGF-C protein in tumors, we quantified the amount of VEGF-C protein in tumors. A dramatically lower level of VEGF-C protein was detected in tumors treated with CaCO 3 nanoparticle-siVEGF-C complex at 18 days after the first injection; whereas tumors treated with CaCO 3 nanoparticle-control plasmid complex showed higher levels of VEGF-C protein (Figure 8d ). We then examined the microlymphatic density in tumors by immunostaining with goat anti-mouse VEGFR-3. The microlymphatic density in tumors from the group treated with CaCO 3 nanoparticle-siVEGF-C complex was significantly reduced as compared with tumors from the group treated with CaCO 3 nanoparticle-control plasmid complex and untreated control (Figures 8a-c) . Meanwhile, we examined the metastatic potential of the tumors treated with either the CaCO 3 nanoparticle-siVEGF-C complex or the CaCO 3 nanoparticle-control siRNA complex. Nude mice injected with the CaCO 3 nanoparticle-siVEGF-C complex or the CaCO 3 nanoparticle-control plasmid complex were killed on day 18 and lymph nodes were examined for metastasis by immunohistochemistry. We observed a significant inhibition in incidence of lymph-node metastasis in the CaCO 3 nanoparticle-siVEGF-C complex group as compared with the control group (Table 1 ). In addition, the frequency of pan-cytokeratin-positive metastatic cells in lymph nodes was significantly lower in the VEGF-C-siRNA-treatment group as compared with the control group (data not shown). Based on the above observations, we believed that the antitumor effect was mainly due to the antilymphangiogenesis effect of the CaCO 3 nanoparticle-siVEGF-C complex group.
Discussion
The overexpression of VEGF-C in tumors is a mark of poor prognosis with respect to disease progression and siRNA targeting vascular endothelial growth factor-C X-w He et al patient survival. 25 For gastric tumors, as for many others, VEGF-C is considered the prominent inducer of tumor lymphangiogenesis. Consequently, a tumor therapy targeting VEGF-C would be particularly efficacious in the treatment of gastric tumor.
siRNAs have been used against several cancer targets, either as synthetic RNA oligonucleotides, 28, 29 or as plasmid-encoded shRNA, 33, 34 which is expected to be efficiently transcribed and subsequently processed to yield the mature, active form of siRNA.
Several ongoing clinical trials are performed to test the use of nanoparticles in gene therapy to treat human genetic disease and cancer. 35, 36 We have reported that calcium phosphate nanoparticle is an effective nonviral vector for gene transferring. 37 In this study, we demonstrate the effectiveness of the nonviral CaCO 3 nanoparticle as a siRNA delivery vehicle for VEGF-C silencing. The CaCO 3 nanoparticle has a diameter of 58 nm, which is much smaller than a normal cell size (1500 nm). The CaCO 3 nanoparticle has positive surface charges of þ 28.6 mV and is capable of forming a CaCO 3 nanoparticle-DNA complex. The CaCO 3 nanoparticle-DNA complex is not disrupted during centrifugation at 10 000 r.p.m. for 10 min, and it protects DNA from degradation in 10% FBS and 10% newborn bovine serum at 37 1C for 12 h. Furthermore, we found that the optimal ratio of CaCO 3 nanoparticle to DNA is 15:1, and the maximal gene expression is observed 48 h after transfection. The CaCO 3 Abbreviations: PBS, phosphate-buffered saline; siRNA, small interfering RNA; VEGF-C, vascular endothelial growth factor-C.
Following treatment with VEGF-CsiRNA, control siRNA or PBS for 18 days. The presence of regional lymph node metastasis was documented and confirmed histologically. *Po0.05 compared to control siRNA-treatment group.
siRNA targeting vascular endothelial growth factor-C X-w He et al experiments (unpublished data). Although the lipofection had a high transfection efficiency (approximately 70%), a large proportion of cell death appeared at 24 h after transfection. The transfection efficiency of CaCO 3 nanoparticle was nearly comparable to those of the commercially available transfection reagents and was higher than that of gelatin-modified nanoparticles (50%). 38 The mechanism of high transfection efficiency could be attributed to the submicrometer size. In addition, the divalent metal cation Ca 2 þ could form ionic complexes with the nucleic acid backbone and may stabilize DNA structures, so the CaCO 3 nanoparticle-DNA complexes can effectively cross cell membranes by ion channel-mediated endocytosis. 39 Because of the dissolution of calcium carbonate in the low acidic medium of endosomal compartments, the calcium carbonate nanoparticles are dissolved in the endosome and destabilize it through osmotic imbalance, and finally deliver the genetic material out into the cytosol. 40 The electrostatic interaction of Ca 2 þ with negatively charged DNA makes the DNA stable against nuclease attack, so that DNA can slowly enter the nucleus without any degradation. The efficient nuclear uptake of DNA from the cytosol is also assisted by Ca 2 þ ions through the deactivation of inositol triphosphate, so that nuclear pore complexes remains wide open, thereby allowing the CaCO 3 nanoparticle-DNA complexes to pass. 40 These results indicate that the CaCO 3 nanoparticle might be used for safe and efficient delivery of the encapsulated DNA in vivo.
To test the efficacy of the VEGF-C siRNA sequence, the expression plasmid pGenesi1-1 siRNA VEGF-C was transfected into SGC-7901 cells by the CaCO 3 nanoparticle procedure. The VEGF-C mRNA expression and protein secretion in the transfected cells were significantly reduced in comparison to cells transfected with a control plasmid. Because of these results, the therapeutic effect of VEGF-C siRNA on lymphangiogenesis and tumor growth in the subcutaneous SGC-7901 cell xenograft were also investigated. The in vivo experiments clearly show that intratumoral injection of VEGF-C siRNA inhibits tumor growth. The histological study demonstrates that the tumor lymphatic density in VEGF-C-siRNA-treated mice was significantly less than that in control mice. Expression of VEGF-C mRNA in VEGF-C-siRNA-treated tumor tissue was also significantly reduced as determined by real-time PCR.
Therefore, we believe that CaCO 3 nanoparticle is an efficient vector for siRNA, and that the CaCO 3 nanoparticle-siRNA-VEGF-C complexes inhibit lymphangiogenesis, regional lymph-node metastasis and primary tumor growth. The project is subsidized by Hunan natural scientific funds, project number: 06JJ20089.
